Benjamin Burnett
Stock Analyst at Wells Fargo
(3.42)
# 947
Out of 5,090 analysts
86
Total ratings
54.84%
Success rate
3.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Maintains: Equal-Weight | $20 → $23 | $21.34 | +5.44% | 3 | Nov 20, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $29.91 | +17.02% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $29.52 | +25.34% | 3 | Nov 13, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $163 → $157 | $149.22 | +5.21% | 2 | Nov 4, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.08 | +177.78% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $56.88 | -13.85% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $69.56 | +75.39% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $27.09 | +154.71% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $35.87 | +89.57% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.43 | +221.68% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $14.33 | +301.26% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $5.02 | +15,437.85% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $16 | $7.49 | +113.62% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.68 | +40.85% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $21.69 | +6.04% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $77.26 | +20.38% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $44 | $45.01 | -2.24% | 2 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $489.31 | -13.55% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $79.64 | -19.64% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $93.29 | +0.76% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $2.22 | +80.59% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.60 | +177.78% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.20 | +1,036.36% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $56.90 | +532.69% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.50 | +3,126.46% | 1 | Jan 6, 2021 |
Avadel Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $21.34
Upside: +5.44%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $29.91
Upside: +17.02%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $29.52
Upside: +25.34%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $163 → $157
Current: $149.22
Upside: +5.21%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.08
Upside: +177.78%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $56.88
Upside: -13.85%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $69.56
Upside: +75.39%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $27.09
Upside: +154.71%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $35.87
Upside: +89.57%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.43
Upside: +221.68%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $14.33
Upside: +301.26%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $5.02
Upside: +15,437.85%
Nov 11, 2025
Maintains: Overweight
Price Target: $18 → $16
Current: $7.49
Upside: +113.62%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.68
Upside: +40.85%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $21.69
Upside: +6.04%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $77.26
Upside: +20.38%
Nov 4, 2025
Maintains: Overweight
Price Target: $48 → $44
Current: $45.01
Upside: -2.24%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $489.31
Upside: -13.55%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $79.64
Upside: -19.64%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $93.29
Upside: +0.76%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $2.22
Upside: +80.59%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.60
Upside: +177.78%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.20
Upside: +1,036.36%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $56.90
Upside: +532.69%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.50
Upside: +3,126.46%